The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis
INTRODUCTION: Although GLP-1 agonists have been shown to reduce cardiovascular events, their effect on the progression of subclinical atherosclerosis is not clear. In this respect, it was planned to evaluate cardiovascular risk markers in obese and diabetic patients receiving exenatide therapy. METH...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Van Yuzuncu Yil University, School of Medicine
2022-07-01
|
| Series: | Van Tıp Dergisi |
| Subjects: | |
| Online Access: | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-09815 |
| _version_ | 1797421373866377216 |
|---|---|
| author | Davut Sakız Murat Çalapkulu Muhammed Erkam Sencar Seyit Murat Bayram İlknur Ozturk Unsal Muhammed Kizilgul Bekir Uçan Mustafa Özbek Erman Çakal |
| author_facet | Davut Sakız Murat Çalapkulu Muhammed Erkam Sencar Seyit Murat Bayram İlknur Ozturk Unsal Muhammed Kizilgul Bekir Uçan Mustafa Özbek Erman Çakal |
| author_sort | Davut Sakız |
| collection | DOAJ |
| description | INTRODUCTION: Although GLP-1 agonists have been shown to reduce cardiovascular events, their effect on the progression of subclinical atherosclerosis is not clear. In this respect, it was planned to evaluate cardiovascular risk markers in obese and diabetic patients receiving exenatide therapy. METHODS: This retrospective study included 56 patients with Type 2 Diabetes Mellitus (DM) with a body mass index (BMI) >35. Demographic, anthropometric and clinic characteristics before and after six-month treatment with exenatide were screened. Cardiovascular risk marker Atherogenic Index of Plasma (AIP), uric acid, carotis intima media thickness (CIMT), HbA1c, fasting blood glucose (FBS) and postprandial blood glucose (TCG) levels were evaluated. RESULTS: Eleven of the fifty-six patients had discontinued exenatide due to side effects, etc. 45 patients (35 females, 10 males; age 50 +- 9.5 years) completed the study. AIP, HbA1c, uric acid, fasting plasma glucose, postprandial glucose, waist circumference, hip circumference, body mass index (BMI), total cholesterol, and triglyceride levels were improved with exenatide treatment. However, no change was detected in CIMT, blood pressure, spot urine albumin/creatinine ratio, LDL, and HDL levels. DISCUSSION AND CONCLUSION: Glycemic parameters, AIP and uric acid levels, which are biochemical predictors of subclinical atherosclerosis, were improved with GLP-1 agonist exetide treatment. However, no change was observed in CIMT measurements. These findings can be interpreted as exenatide therapy, can slow down the progression of subclinical atherosclerosis, but has no effect on existing atherosclerotic plaque. |
| first_indexed | 2024-03-09T07:14:58Z |
| format | Article |
| id | doaj.art-190f2133660c4706a5823e3cd8027b9e |
| institution | Directory Open Access Journal |
| issn | 2587-0351 |
| language | English |
| last_indexed | 2024-03-09T07:14:58Z |
| publishDate | 2022-07-01 |
| publisher | Van Yuzuncu Yil University, School of Medicine |
| record_format | Article |
| series | Van Tıp Dergisi |
| spelling | doaj.art-190f2133660c4706a5823e3cd8027b9e2023-12-03T08:30:56ZengVan Yuzuncu Yil University, School of MedicineVan Tıp Dergisi2587-03512022-07-0129326727410.5505/vtd.2022.09815VTD-09815The Effect of GLP-1 Agonist Treatment On Subclinical AtherosclerosisDavut Sakız0Murat Çalapkulu1Muhammed Erkam Sencar2Seyit Murat Bayram3İlknur Ozturk Unsal4Muhammed Kizilgul5Bekir Uçan6Mustafa Özbek7Erman Çakal8Mardin Training and Research Hospital, Department of Endocrinology and Metabolism, MardinUniversity of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, AnkaraUniversity of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, AnkaraNevsehir State Hospital, Department of Endocrinology and Metabolism, NevsehirUniversity of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, AnkaraUniversity of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, AnkaraUniversity of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, AnkaraUniversity of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, AnkaraUniversity of Health Sciences, Diskapi Yildirim Beyazit Training and Research Hospital, Department of Endocrinology and Metabolism, AnkaraINTRODUCTION: Although GLP-1 agonists have been shown to reduce cardiovascular events, their effect on the progression of subclinical atherosclerosis is not clear. In this respect, it was planned to evaluate cardiovascular risk markers in obese and diabetic patients receiving exenatide therapy. METHODS: This retrospective study included 56 patients with Type 2 Diabetes Mellitus (DM) with a body mass index (BMI) >35. Demographic, anthropometric and clinic characteristics before and after six-month treatment with exenatide were screened. Cardiovascular risk marker Atherogenic Index of Plasma (AIP), uric acid, carotis intima media thickness (CIMT), HbA1c, fasting blood glucose (FBS) and postprandial blood glucose (TCG) levels were evaluated. RESULTS: Eleven of the fifty-six patients had discontinued exenatide due to side effects, etc. 45 patients (35 females, 10 males; age 50 +- 9.5 years) completed the study. AIP, HbA1c, uric acid, fasting plasma glucose, postprandial glucose, waist circumference, hip circumference, body mass index (BMI), total cholesterol, and triglyceride levels were improved with exenatide treatment. However, no change was detected in CIMT, blood pressure, spot urine albumin/creatinine ratio, LDL, and HDL levels. DISCUSSION AND CONCLUSION: Glycemic parameters, AIP and uric acid levels, which are biochemical predictors of subclinical atherosclerosis, were improved with GLP-1 agonist exetide treatment. However, no change was observed in CIMT measurements. These findings can be interpreted as exenatide therapy, can slow down the progression of subclinical atherosclerosis, but has no effect on existing atherosclerotic plaque.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-09815exenatideincretinatherosclerosisdiabetes mellituscardiovascular riskobesity |
| spellingShingle | Davut Sakız Murat Çalapkulu Muhammed Erkam Sencar Seyit Murat Bayram İlknur Ozturk Unsal Muhammed Kizilgul Bekir Uçan Mustafa Özbek Erman Çakal The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis Van Tıp Dergisi exenatide incretin atherosclerosis diabetes mellitus cardiovascular risk obesity |
| title | The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis |
| title_full | The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis |
| title_fullStr | The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis |
| title_full_unstemmed | The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis |
| title_short | The Effect of GLP-1 Agonist Treatment On Subclinical Atherosclerosis |
| title_sort | effect of glp 1 agonist treatment on subclinical atherosclerosis |
| topic | exenatide incretin atherosclerosis diabetes mellitus cardiovascular risk obesity |
| url | https://jag.journalagent.com/z4/download_fulltext.asp?pdir=vtd&un=VTD-09815 |
| work_keys_str_mv | AT davutsakız theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT muratcalapkulu theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT muhammederkamsencar theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT seyitmuratbayram theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT ilknurozturkunsal theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT muhammedkizilgul theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT bekirucan theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT mustafaozbek theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT ermancakal theeffectofglp1agonisttreatmentonsubclinicalatherosclerosis AT davutsakız effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT muratcalapkulu effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT muhammederkamsencar effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT seyitmuratbayram effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT ilknurozturkunsal effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT muhammedkizilgul effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT bekirucan effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT mustafaozbek effectofglp1agonisttreatmentonsubclinicalatherosclerosis AT ermancakal effectofglp1agonisttreatmentonsubclinicalatherosclerosis |